RECRUITING

Reward Processing and Depressive Subtypes: Identifying Neural Biotypes

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Deficits in motivation and pleasure are common in depression, and thought to be caused by alterations in the ways in which the brain anticipates, evaluates, and adaptively uses reward-related information. However, reward processing is a complex, multi-circuit phenomenon, and the precise neural mechanisms that contribute to the absence or reduction of pleasure and motivation are not well understood. Variation in the clinical presentation of depression has long been a rule rather than an exception, including individual variation in symptoms, severity, and treatment response. This heterogeneity complicates understanding of depression and thwarts progress toward disease classification and treatment planning. Discovery of depression-specific biomarkers that account for neurobiological variation that presumably underlies distinct clinical manifestations is critical to this larger effort.

Official Title

Reward Processing and Depressive Subtypes: Identifying Neural Biotypes Related to Suicide Risk, Resilience, and Treatment Response

Quick Facts

Study Start:2021-06-01
Study Completion:2025-09-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06080646

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 70 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 18-70 years with a diagnosis of major depressive disorder (MDD) for MDD group, or without for unaffected comparison (UC) group
  2. * Negative metal screen for MRI safety
  3. * Normal (or corrected to normal) vision
  1. * Past or present neurological problems (including seizures and head trauma resulting in neurological or cognitive symptoms)
  2. * Loss of consciousness (LOC) greater than 30 minutes or any LOC with neurologic symptoms
  3. * Major medical conditions (e.g., seizure disorders, treatment with anticonvulsant medication, endocrine disorders, significant cardiac pathology)
  4. * Substance dependence, within the past year, or failed urine toxicology on the day of neuroimaging sessions
  5. * Known claustrophobia
  6. * Current Pregnancy
  7. * IQ estimate \< 70

Contacts and Locations

Study Contact

Jason Hemmerle, MBA
CONTACT
415 221 4810
jason.hemmerle@ucsf.edu
Kaitlyn Dal Bon, BA
CONTACT
415 221 4810
kaitlyn.dalbon@ucsf.edu

Principal Investigator

Susanna L Fryer, PhD
PRINCIPAL_INVESTIGATOR
University of California, San Francisco

Study Locations (Sites)

San Francisco Healthcare System
San Francisco, California, 94121
United States

Collaborators and Investigators

Sponsor: San Francisco Veterans Affairs Medical Center

  • Susanna L Fryer, PhD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-06-01
Study Completion Date2025-09-01

Study Record Updates

Study Start Date2021-06-01
Study Completion Date2025-09-01

Terms related to this study

Keywords Provided by Researchers

  • reward
  • motivation
  • EEG
  • fMRI
  • MRI
  • functional MRI
  • amotivation
  • avolition
  • suicidality
  • suicide

Additional Relevant MeSH Terms

  • Depression
  • Depressive Disorder
  • Major Depressive Disorder
  • Major Depressive Episode
  • Depressive Symptoms
  • Anhedonia